Welcome to our dedicated page for Conmed SEC filings (Ticker: CNMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CONMED Corporation filings document the regulatory record for a medical technology company with common stock listed on the NYSE under the symbol CNMD. Its Form 8-K reports cover quarterly and annual operating results, investor presentations furnished under Regulation FD, finance leadership changes, and portfolio actions involving gastroenterology products and distribution agreements.
The company’s proxy materials disclose board matters, annual meeting voting, executive compensation, equity awards, and related governance information. CONMED’s filing record also identifies its capital stock structure, including common stock with $0.01 par value, and provides formal exhibits for earnings releases, presentations, transition agreements, and other material corporate updates.
Martin Celine Christine reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp director Celine Christine Martin received a grant of restricted stock units as equity compensation. She was awarded 5,603 RSUs tied to CONMED common stock at a price of $0.00 per unit. Following this grant, her reported holdings of this RSU award total 5,603 units.
Each RSU represents a contingent right to receive one share of CONMED common stock under the company’s 2025 Long-Term Incentive Plan. The RSUs generally vest 100% after one year, meaning she will receive the underlying shares if vesting conditions are met and the award does not expire earlier.
Mirviss Jeffrey B. reported acquisition or exercise transactions in this Form 4 filing.
CONMED Corp director Jeffrey B. Mirviss reported a grant of 5,603 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of CONMED common stock and was awarded under the company’s 2025 Long-Term Incentive Plan. The RSUs generally vest 100% after one year, and Mirviss now holds 5,603 RSUs directly as reported in this filing. This is a compensation-related equity award rather than an open-market stock purchase or sale.
CONMED Corp filed an initial insider ownership report for Jeffrey B. Mirviss, who became a Director on July 1, 2026. The filing lists his position in the company’s Common Stock.
The report shows he held 0 shares of Common Stock following the reported date, meaning no beneficial ownership is reported at this time.
CONMED Corp director Celine Christine Martin has filed an initial Form 3 reporting her holdings in the company’s common stock. The filing notes that she became a Director of CONMED on July 1, 2026 and currently reports no directly owned shares of CONMED common stock. Form 3 serves as the starting point for tracking any future changes in her ownership.
CONMED Corporation has appointed John E. Gallagher as Executive Vice President and Chief Financial Officer, effective July 15, 2026. He will also serve as principal financial and principal accounting officer, succeeding prior CFO leadership while former CFO Todd Garner remains in an advisory role through November 2, 2026.
Gallagher brings nearly three decades of finance experience from Certara, Cue Health, Becton Dickinson, General Electric and Ford. His compensation includes a $650,000 base salary, a target annual bonus at 85% of salary, equity grants under CONMED’s 2025 Long-Term Incentive Plan and a make-whole RSU award.
The agreement provides severance protection under the Executive Severance Plan, with higher cash multipliers and benefits if termination without cause or resignation for good reason occurs within two years after a change in control. Interim finance leaders Patrick Beyer and Kimberly Lockwood revert to their prior roles once Gallagher starts.
CONMED Corporation entered into separate, privately negotiated purchase agreements to repurchase approximately $645.2 million aggregate principal amount of its 2.25% Convertible Senior Notes due 2027 for about $637.2 million in cash.
The purchases from existing noteholders are expected to close on June 15, 2026, subject to customary closing conditions.
CONMED Corp director David M. Bronson reported compensation-related equity activity. On June 2, 2026, he exercised 668 restricted stock units into the same number of common shares, bringing his direct common stock holdings to 17,909 shares.
On June 1, 2026, he received a new award of 5,772 RSUs under CONMED’s 2025 Long-Term Incentive Plan. Each RSU represents a contingent right to one share of common stock and generally vests 100% after one year. These transactions are reported as grants and derivative exercises rather than open-market buys or sells.
CONMED Corp director LaVerne H. Council reported compensation-related equity activity. On June 2, 2026, Council exercised 668 RSUs into the same number of common shares, bringing direct common stock holdings to 4,716 shares after the transaction. There were no open-market purchases or sales.
On June 1, 2026, Council received a grant of 5,772 RSUs under CONMED’s 2025 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock and is generally scheduled to vest 100% after one year, aligning the director’s compensation with future company performance.
CONMED Corp director Kim Kelderman received a grant of 5,772 restricted stock units (RSUs) as equity compensation. Each RSU represents a contingent right to receive one share of CONMED common stock under the company’s 2025 Long-Term Incentive Plan.
The RSUs generally vest 100% after one year, aligning Kelderman’s compensation with shareholder interests over that period. Following this award, Kelderman holds 5,772 RSUs directly, which may convert into the same number of common shares if the vesting conditions are satisfied.
CONMED Corp director Charles Farkas reported routine equity compensation activity. On June 1, 2026, he received a grant of 5,772 RSUs, each representing a right to one share of common stock under the Company’s 2025 Long-Term Incentive Plan, generally vesting 100% after one year. On June 2, 2026, he exercised 668 RSUs into the same number of CONMED common shares at a stated price of $0.00 per share, bringing his direct common stock holdings to 15,527 shares. After the exercise, the specific 668-unit RSU award shows no remaining balance, while the newer 5,772-unit grant reflects his continuing derivative position.